Search

JUPITER, Fla. -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Stifel 2024 Healthcare Conference [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis and the unaudited interim financial statements included [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Caution: This discussion and analysis may contain predictions, estimates and other forward-looking [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632024-11-072024-11-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

ENPNewswire-November 4, 2024--Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 01112024 - JUPITER - Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) [...]

JUPITER, Fla. -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday, December 10, 2024 from 10:30 a.m. to [...]

ENPNewswire-October 24, 2024--Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 23102024 - JUPITER - Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This Quarterly Report on Form 10-Q contains 'forward-looking statements' as defined in [...]

ENPNewswire-October 16, 2024--invIOs raises EUR8.2 million in a Series A to finance pipeline progress in immuno-oncology (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 15102024 - Vienna, Austria - invIOs GmbH ('invIOs'), [...]

2024 NOV 27 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

2024 NOV 20 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

2024 OCT 2 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

ENPNewswire-September 9, 2024--Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI, the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (C)2024 ENPublishing - http://www.enpublishing.co.uk Release [...]

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria and kidney function [...]

(EDGAR Online via COMTEX) -- FALSE000100528605/2600010052862024-08-152024-08-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act [...]

JUPITER, Fla. -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the H.C. Wainwright 26th Annual [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following information should be read in conjunction with our unaudited condensed [...]

(EDGAR Online via COMTEX) -- Prospectus Supplement No. 3 Filed pursuant to Rule 424(b)(3) (to prospectus dated March 27, 2024) Registration No. 333-274863 [[Image Removed: img45989159_0.jpg]] DIANTHUS THERAPEUTICS, INC. 21,326,988 [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Forward Looking Statements This Quarterly Report on Form 10-Q and other written [...]

Shares of Ligand Pharmaceuticals Incorporated (LGND) traded higher to a new 52-week high in today's trading. The stock is up 3.06% to EUR101.00 at the last check Tuesday. Ligand Pharmaceuticals [...]

JUPITER: LIGAND PHARMACEUTICALS INCORPORATED has issued the following news release: Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a definitive agreement to acquire APEIRON Biologics AG, [...]

ENPNewswire-July 9, 2024--Ligand to Acquire APEIRON Biologics AG for $100 Million (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 08072024 - JUPITER - Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it [...]

Acquisition provides Ligand with the royalty rights to QARZIBA[R], a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A. QARZIBA is the sixth key [...]

Ligand Pharmaceuticals Incorporated has unveiled that its collaborator Merck, known as MSD outside the United States and Canada, has received approval from the U.S. Food and Drug Administration (FDA) for [...]

2024 JUL 24 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Ligand Pharmaceuticals Inc. reported that it has entered into a definitive agreement to acquire APEIRON Biologics AG, which holds royalty rights to QARZIBA (dinutuximab beta) for the treatment of high-risk [...]

2024 JUL 17 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]